AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.160

-0.450-2.88%

Volume:2.58M

Turnover:39.09M

Market Cap:5.14B

PE:110.46

High:15.510

Open:15.410

Low:14.880

Close:15.610

52wk High:18.220

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.36

T/O Rate:0.94%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.137

EPS(LYR):-0.030

ROE:7.36%

ROA:2.71%

PB:7.32

PE(LYR):-499.37

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Announces Shareholder Meeting

Australia Shares Set to Resume Recent Slide

Australia's Telix Pharma Agrees to Buy Germany's ITM Isotope for About $1.65 Billion

Telix Pharmaceuticals Limited - Telix and Itm Join Forces to Create Radiopharma Powerhouse

THOMSON REUTERS

Telix Pharmaceuticals - After Adjustments, Itm Shareholders Expected to be Paid Us$1.25 Bln in Telix Shares at US$11.841/Shr

THOMSON REUTERS

Telix Pharmaceuticals - Additional Contingent Consideration of up to Us$700 Mln upon Achievement of Future Regulatory Approvals, Others

THOMSON REUTERS

Telix Pharmaceuticals Limited - Signed a Strategic Agreement to Lead a Merger with Itm Isotope Technologies Munich Se

THOMSON REUTERS

Telix Pharmaceuticals Limited - Upfront Consideration of Us$1.65 Bln

THOMSON REUTERS

Telix Pharmaceuticals - Combined Organization is Expected to Generate Unaudited Pro Forma 2026 Revenue and Income Exceeding Us$1.3 Billion

THOMSON REUTERS

PDI Gold And 2 Australian Founder Led Growth Stocks

Simply Wall St.

Australia's Telix Set for Best Week in 7 Months After FDA Nod for Drug

Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says

MT Newswires Live

Australia's Telix Extends Gains After FDA Approval for Brain Cancer Imaging Drug

Telix Pharma CFO Darren Charlton Smith Acquires 2,071 Common Shares for AUD 19,999.58

FDA Approves Telix Brain Cancer Imaging Drug Pixclara for Glioma PET Scans

Telix Pharmaceuticals Limited-FDA Approves Telix Brain Cancer Imaging Drug Pixclara

THOMSON REUTERS

ASX Biggest Gainers

MT Newswires Live

Australia's Telix Pharma Gains on Completing Enrollment in Late-Stage Study

Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging

MT Newswires Live

Telix Completes Enrollment in Phase 3 Bipass Study, Aligns with FDA on Nda Pathway

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/TLX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.16,"timestamp":1790921520000,"preClose":15.61,"halted":0,"volume":2579339,"delay":0,"changeRate":-0.028827674567584838,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13723834202109522,"marketStatus":"Market Closed","change":-0.45,"latestTime":"10-02 16:12:00 AEST","open":15.41,"high":15.51,"low":14.88,"amount":39088106,"amplitude":0.040359,"askPrice":15.25,"askSize":65,"bidPrice":15.03,"bidSize":1666,"shortable":3,"etf":0,"ttmEps":0.13723834202109522,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":15.61,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":1.362455698335538,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.61,"auctionPrice":15.16,"auctionVolume":323724,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921417000}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.030358,"volumeRatio":1.362455698335538,"shares":338721355,"dividePrice":0,"high":15.51,"amplitude":0.040359,"preClose":15.61,"low":14.88,"week52Low":8.26,"pbRate":"7.32","psRate":"4.01","week52High":18.22,"institutionHeld":0,"latestPrice":15.16,"committee":0.924899,"eps":0.13723834202109522,"divideRate":0,"volume":2579339,"delay":0,"ttmEps":0.13723834202109522,"open":15.41,"prevYearClose":11.2,"prevWeekClose":15.9,"prevMonthClose":15.72,"prevQuarterClose":15.72,"fiveDayClose":15.9,"twentyDayClose":16.47,"sixtyDayClose":16.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669136711","title":"Telix Pharmaceuticals Announces Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136711","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669136711?lang=en_us&edition=fundamental","pubTime":"2026-09-21 09:56","pubTimestamp":1789955791,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals announces shareholder meetingTelix Pharmaceuticals will hold an extraordinary general meeting in November 2026.Shareholders will vote on the proposed merger to acquire ITM Isotop","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLbGJGlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669387401","title":"Australia Shares Set to Resume Recent Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2669387401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669387401?lang=en_us&edition=fundamental","pubTime":"2026-09-21 07:51","pubTimestamp":1789948260,"startTime":"0","endTime":"0","summary":"2351 GMT - Australian stocks look set to resume their recent slide in early trade, adding to losses compiled across three consecutive weekly declines. ASX futures are down by almost 0.7% ahead of Monday's session, suggesting that the S&P/ASX 200 will extend the 3.8% decline recorded so far in September. Investors are waiting on next week's Reserve Bank meeting, which is expected to end with an interest-rate increase and hawkish commentary on the potential for further increases. Ahead of Monday's open, Perpetual rejected EQT AB's best and final takeover proposal, Ingenia rejected Warburg Pincus's improved offer, and Telix Pharmaceuticals agreed to buy isotope supplier ITM for up to US$2.35 billion. Resolute Mining downgraded its 2026 gold production and cost guidance on challenges in Mali.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7506","RSG.AU","BK7104","TLX.AU","PPT.AU","BK7067","BK7062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669018008","title":"Australia's Telix Pharma Agrees to Buy Germany's ITM Isotope for About $1.65 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2669018008","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669018008?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:55","pubTimestamp":1789944927,"startTime":"0","endTime":"0","summary":"Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billionSept 21 (Reuters)-Australia's Telix PharmaceuticalsTLX.AXsaid on Monday it has agreed to acquire Germany-based ITM I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nL1N45C06M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669804721","title":"Telix Pharmaceuticals Limited - Telix and Itm Join Forces to Create Radiopharma Powerhouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2669804721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669804721?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669804081","title":"Telix Pharmaceuticals - After Adjustments, Itm Shareholders Expected to be Paid Us$1.25 Bln in Telix Shares at US$11.841/Shr","url":"https://stock-news.laohu8.com/highlight/detail?id=2669804081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669804081?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669470180","title":"Telix Pharmaceuticals - Additional Contingent Consideration of up to Us$700 Mln upon Achievement of Future Regulatory Approvals, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2669470180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669470180?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669180477","title":"Telix Pharmaceuticals Limited - Signed a Strategic Agreement to Lead a Merger with Itm Isotope Technologies Munich Se","url":"https://stock-news.laohu8.com/highlight/detail?id=2669180477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669180477?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669180474","title":"Telix Pharmaceuticals Limited - Upfront Consideration of Us$1.65 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2669180474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669180474?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669180403","title":"Telix Pharmaceuticals - Combined Organization is Expected to Generate Unaudited Pro Forma 2026 Revenue and Income Exceeding Us$1.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2669180403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669180403?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:38","pubTimestamp":1789943881,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PK:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668888661","title":"PDI Gold And 2 Australian Founder Led Growth Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2668888661","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668888661?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:29","pubTimestamp":1789748965,"startTime":"0","endTime":"0","summary":"Central banks are lifting interest rates again, and history shows that higher borrowing costs often hit fast growers hardest. Australian companies where founders and executives hold big stakes can sometimes weather that pressure better, because management feels every share price move in their own net worth. This article looks at three fast growing, high insider ownership stocks from our screener and explains why each might deserve a spot on your watchlist.\nThe three stocks below are just a...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice2-card/1788948823050","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice2-card/1788948823050"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/pdi-gold-shares/news/pdi-gold-and-2-australian-founder-led-growth-stocks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/pdi-gold-shares/news/pdi-gold-and-2-australian-founder-led-growth-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USD.AU","PDI","XJO.AU","QFN.AU","QRE.AU","BBOZ.AU","XKO.AU","SLF.AU","GEAR.AU","VAS.AU","IIGF.AU","BK7501","BEAR.AU","OZR.AU","STW.AU","IMLC.AU","ZYAU.AU","PDI.AU","BK4139","VAP.AU","IOZ.AU","BK7067","OZF.AU","MSB.AU","E200.AU","IISV.AU","DACE.AU","GIVE.AU","BK7508","USD","XAO.AU","TLX.AU","EIGA.AU","BK7104","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919180","title":"Australia's Telix Set for Best Week in 7 Months After FDA Nod for Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668919180?lang=en_us&edition=fundamental","pubTime":"2026-09-18 10:20","pubTimestamp":1789698036,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix set for best week in 7 months after FDA nod for drug** Shares of Telix PharmaceuticalsTLX.AXgain as much as 3.8% to A$18.110** Stock on track to log 14.6% gain for the week, its","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL4N45A052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667487616","title":"Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667487616","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667487616?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:31","pubTimestamp":1789450283,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  earnings per share  forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration  approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography  drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","BK7047","PET.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667961665","title":"Australia's Telix Extends Gains After FDA Approval for Brain Cancer Imaging Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667961665","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667961665?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:20","pubTimestamp":1789449641,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix extends gains after FDA approval for brain cancer imaging drug** Shares of Telix PharmaceuticalsTLX.AXextend gains into another day, rising as much as 11.5% to A$18.22, their hi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4N4570CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691827","title":"Telix Pharma CFO Darren Charlton Smith Acquires 2,071 Common Shares for AUD 19,999.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691827","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691827?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:20","pubTimestamp":1789428051,"startTime":"0","endTime":"0","summary":"Telix Pharma CFO Darren Charlton Smith acquires 2,071 common shares for AUD 19,999.58Telix Pharmaceuticals: Group Chief Financial Officer Darren Charlton Smith increased his stake via a purchase of 2,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL487S5l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telix Pharma CFO Darren Charlton Smith Acquires 2,071 Common Shares for AUD 19,999.58","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667633236","title":"FDA Approves Telix Brain Cancer Imaging Drug Pixclara for Glioma PET Scans","url":"https://stock-news.laohu8.com/highlight/detail?id=2667633236","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667633236?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:32","pubTimestamp":1789338774,"startTime":"0","endTime":"0","summary":"FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scansFDA cleared Telix’s Pixclara, an F-18 PET imaging drug for glioma, marking the first approved FET-PET agent in the US.Label co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260913:nNDLb2FtNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667633451","title":"Telix Pharmaceuticals Limited-FDA Approves Telix Brain Cancer Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667633451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667633451?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:21","pubTimestamp":1789338100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260913:nTUE6SCT8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033823","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:14","pubTimestamp":1788405296,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Thursday.Southgold 2 : +8%, AU$12.27Phylogica : +7%, AU$2.61OrezOne : +6%, AU$2.75Block : +5%, AU$113.81Telix Pharmaceuticals : +5%, AU$16.44Kingsgate Consolidated : +4%, AU$5.39Deep Yellow : +4%, AU$1.61Resolute Mining : +4%, AU$1.44Perseus Mining : +4%, AU$6.66Life360 : +4%, AU$19.92","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7158","ORE.AU","PYC.AU","SX2.AU","PRU.AU","RSG.AU","BK7083","TLX.AU","XYZ.AU","KCN.AU","TLX","BK7016","BK4139","BK7506","BK7104","360.AU","DYL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389538","title":"Australia's Telix Pharma Gains on Completing Enrollment in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389538","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664389538?lang=en_us&edition=fundamental","pubTime":"2026-09-02 12:04","pubTimestamp":1788321859,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharma gains on completing enrollment in late-stage study** ASX-listed shares of Telix PharmaceuticalsTLX.AXrise 4.1% to A$15.89, on track for biggest one day pct gain since Aug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4N44U0BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867645","title":"Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867645","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867645?lang=en_us&edition=fundamental","pubTime":"2026-09-02 08:50","pubTimestamp":1788310213,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664861070","title":"Telix Completes Enrollment in Phase 3 Bipass Study, Aligns with FDA on Nda Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2664861070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664861070?lang=en_us&edition=fundamental","pubTime":"2026-09-02 06:18","pubTimestamp":1788301129,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA3XXHQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}